Agents and Actions

, Volume 18, Issue 3–4, pp 288–293 | Cite as

Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs?

  • Martin K. Church
Histamine and Kinins Proceedings of the Symposium ‘The Mast Cell Revisited’ November 8, 1984 New York, USA

Conclusions

The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug.

Keywords

Asthma Beneficial Effect Mast Cell Inflammatory Mediator Chemical Modification 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    J.B.L. Howell andR.E.C. Altounyan,A double blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma, Lancet2, 539–542 (1967).PubMedGoogle Scholar
  2. [2]
    J.S.G. Cox,Disodium cromoglycate (FPL 670, ‘Intal’): a specific inhibitor of reaginic antigen-antibody mechanisms, Nature (Lond.)81, 1328–1329 (1967).Google Scholar
  3. [3]
    M.K. Church,Cromoglycate-like anti-allergic drugs: a review, Drugs of Today14, 281–341 (1978).Google Scholar
  4. [4]
    K. Ishizaka andT. Ishizaka,Identification of gamma-E antibodies as a carrier of reaginic activity, J. Immunol.99, 1187–1198 (1967).PubMedGoogle Scholar
  5. [5]
    S.G.O. Johansson,Raised levels of a new immunoglobulin class (IgND) in asthma, Lancet2, 951–953 (1967).PubMedGoogle Scholar
  6. [6]
    D.J. Stechschulte, R.P. Orange andK.F. Austen,Immunochemical and biologic properties of rat IgE, J. Immunol.105, 1082–1086 (1970).PubMedGoogle Scholar
  7. [7]
    T.S.C. Orr,Recent developments concerning the mast cell and the mode of action of disodium cromoglycate, Acta Allergol.12 (Suppl.), 13–29 (1975).Google Scholar
  8. [8]
    T.S.C. Orr, J. Gwilliam andJ.S.G. Cox,Studies on passive cutaneous anaphylaxis in the rat with disodium cromoglycate. II A comparison of the rat anti-DNP 7S gamma 2 and rat reagin induced cutaneous reactions, Immunology21, 405–407 (1971).PubMedGoogle Scholar
  9. [9]
    F.L. Pearce, A.D. Befus, J. Gauldie andJ. Bienenstock,Mucosal mast cells. II Effects of anti-allergic compounds on histamine secretion by isolated intestinal mast cells, J. Immunol.128, 2481–2486 (1982).PubMedGoogle Scholar
  10. [10]
    J.C. Foreman, M.B. Hallett andJ.L. Mongar,Site of action of the anti-allergic drugs cromoglycate and doxantrazole. Br. J. Pharmacol.59, 473P-474P (1977).Google Scholar
  11. [11]
    F.L. Pearce,Calcium and histamine secretion from mast cells, Prog. Med. Chem.19, 59–109 (1982).PubMedGoogle Scholar
  12. [12]
    A.C. Roy andB.T. Warren,Inhibition of cAMP phosphodiesterase by disodium cromoglycate, Biochem. Pharmacol.23, 917–920 (1974).PubMedGoogle Scholar
  13. [13]
    C. Sung, H.L. Saunders, R.D. Krell andL.W. Chakrin,Studies on the mechanism of tachyphylaxis to disodium cromoglycate, Int. Archs Allergy Appl. Immunol.55, 374–384 (1977).Google Scholar
  14. [14]
    M.K. Church, Biochemical basis of pulmonary and anti-allergic drugs. InPulmonary and anti-allergic drugs, pp. 43–121 (Ed.J.P. Devlin). Wiley, New York 1985.Google Scholar
  15. [15]
    W. Sieghart, T.C. Theoharides, S.L. Alper, W.W. Douglas andP. Greengard,Calcium dependent protein phosphorylation during secretion by exocytosis in the mast cell, Nature (Lond.)275, 329–331 (1978).Google Scholar
  16. [16]
    E. Wells andJ. Mann,Phosphorylation of a mast cell protein in response to treatment with anti-allergic compounds. Implications for the mode of action of sodium cromoglycate, Biochem. Pharmacol.32, 837–842 (1983).PubMedGoogle Scholar
  17. [17]
    K.D. Young andM.K. Church,Passive anaphylaxis in human lung fragments as a model for testing antiallergic drugs: its variability and constraints, Int. Archs Allergy Appl. Immunol.70, 138–142 (1983).Google Scholar
  18. [18]
    M.K. Church, S.T. Holgate andG.J-K. Pao,Histamine release from mechanically and enzymatically dispersed human lung mast cells: inhibition by salbutamol and cromoglycate, Br. J. Pharmacol.79 (Suppl), 374P (1983).Google Scholar
  19. [19]
    K.C. Flint, K.B.P. Leung, F.L. Pearce, B.N. Hudspith, J. Brostoff andN.McI. Johnson,Human mast cells recovered by bronchoalveolar lavage: their morphology, histamine release and the effects of sodium cromoglycate, Clin. Science68, 427–437 (1985).Google Scholar
  20. [20]
    P.H. Howarth, S.R. Durham, T.H. Lee, A.B. Kay, M.K. Church andS.T. Holgate,Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergic bronchial provocation in asthma, Am. Rev. Respir. Dis.132, 986–992 (1985).PubMedGoogle Scholar
  21. [21]
    S.E. Davies,Effect of disodium cromoglycate on exercise-induced asthma, Br. Med. J.3, 593–594 (1968).PubMedGoogle Scholar
  22. [22]
    M.G. Harries, P.S. Burge, I. O'Brien, O. Cromwell andJ. Pepys,Blood histamine after exercise, Clin. Allergy9, 437–441 (1979).PubMedGoogle Scholar
  23. [23]
    P.H. Howarth, G.J-K. Pao, M.K. Church andS.T. Holgate,Exercise and isocapnic hyperventilation-induced bronchoconstriction in asthma: relevance of circulating basophils to measurement of plasma histamine, J. Allergy Clin. Immunol.73, 391–399 (1984).PubMedGoogle Scholar
  24. [24]
    F.J. Breslin, E.R. McFadden andR.H. Ingram,The effects of cromolyn sodium on the airway response to hypnoea and cold air in asthma, Am. Rev. Respir. Dis.122, 11–16 (1980).Google Scholar
  25. [25]
    M.G. Harries, P.E.G. Parkes, M.H. Lessof andT.S.C. Orr,Role of bronchial irritant receptors in asthma, Lancet1, 5–7 (1981).PubMedGoogle Scholar
  26. [26]
    B.T. Butcher,Inhalation challenge and pharmacologic studies of toluene di-isocyanate (TDI) sensitive workers, J. Allergy Clin. Immunol.64, 146–152 (1979).PubMedGoogle Scholar
  27. [27]
    M.J. Cushley, M.K. Church, G.J-K. Pao andS.T. Holgate,Adenosine induced bronchoconstriction is not caused by enhanced immunological release of mast cell mediators, Br. J. Clin. Pharmacol.14, 607P (1982).Google Scholar
  28. [28]
    H. Booij-Nord, N.G.M. Orie andK. DeVries,Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglycate and prednisolone, J. Allergy Clin. Immunol.48, 344–354 (1971).PubMedGoogle Scholar
  29. [29]
    B. Hegardt, R. Pauwels, M. Van der Straaten,Inhibitory effect of KWD 2131, terbutaline and DSCG on the immediate and late allergen-induced bronchoconstriction,Allergy 36, 115–122 (1981).PubMedGoogle Scholar
  30. [30]
    G.L. Larsen, M.P. Shampain, W.R. Marsh andB.L. Behrens, Animal model of the late asthmatic reaction to antigen challenge. InAsthma: physiology, immunopharmacology and treatment, pp. 245–258 (EdsA.B. Kay, K.F. Austen andL.M. Lichtenstein). Academic Press, London 1984.Google Scholar
  31. [31]
    A.B. Kay andT.H. Lee,Neutrophil chemotactic peptide of anaphylaxis, J. Allergy Clin. Immunol.70, 317–320 (1982).PubMedGoogle Scholar
  32. [32]
    A.B. Kay, G.M. Walsh, G.M. Moqbel, A.J. MacDonald, T. Nagakura, M.P. Carrol andM.B. Richardson,Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. Submitted for publication.Google Scholar
  33. [33]
    D.R. Buckle, Disodium cromoglycate and compounds with similar activities. InDevelopment of anti-asthma drugs, pp. 261–296 (EdsD.R. Buckle andH. Smith). Butterworths, London 1984.Google Scholar
  34. [34]
    J.P. Devlin andK.D. Hargrave, Pulmonary and antiallergic drugs: Design and synthesis. InPulmonary and antiallergic drugs, pp. 191–316 (Ed.J.P. Devlin). Wiley, New York 1985.Google Scholar
  35. [35]
    G.D. Watt, T.C. Bui, A.K. Bewtra andR.G. Townley,Protective effects of lodoxamide tromethamine on allergen inhalation challenge, J. Allergy Clin. Immunol.66, 286–294 (1980).PubMedGoogle Scholar
  36. [36]
    N. Eiser, H1-antihistamines. InDevelopment of antiasthmatic drugs, pp. 121–131 (EdsD.R. Buckle andH. Smith). Butterworths, London 1984.Google Scholar
  37. [37]
    J.S. Mann, P. Clement, A.Q. Sheridan, I. Soryal, A.J. Fairfax andS.T. Holgate,Inhaled lodoxamide tromethamine in the treatment of perennial asthma: A double blind placebo controlled study, J. Allergy Clin. Immunol.76, 83–90 (1985).PubMedGoogle Scholar
  38. [38]
    S.R. Walker,The fate of [ 14C]disodium cromoglycate in man, J. Pharm. Pharmacol.24, 525–531 (1972).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1986

Authors and Affiliations

  • Martin K. Church
    • 1
  1. 1.Clinical Pharmacology, Centre BlockSouthampton General HospitalSouthamptonUK

Personalised recommendations